And anthranilate, derived from the catabolism of kynurenine by kynureninase, was upregulated in correlation with the prostate‐specific antigen (PSA) level of prostate cancer patients [60] and was supported to promote tumor immune infiltration [61]. Here, KYNU is linked to prostate carcinoma.